Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Other Operating Expenses (2022 - 2024)

Dianthus Therapeutics has reported Other Operating Expenses over the past 3 years, most recently at -$4.8 million for Q4 2024.

  • Quarterly results put Other Operating Expenses at -$4.8 million for Q4 2024, down 189.29% from a year ago — trailing twelve months through Sep 2025 was -$4.8 million (down 189.29% YoY), and the annual figure for FY2024 was -$4.8 million, changed.
  • Other Operating Expenses for Q4 2024 was -$4.8 million at Dianthus Therapeutics, down from $5.4 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for DNTH hit a ceiling of $5.4 million in Q4 2023 and a floor of -$18.0 million in Q1 2023.
  • Median Other Operating Expenses over the past 3 years was -$6.0 million (2023), compared with a mean of -$7.4 million.
  • Biggest five-year swings in Other Operating Expenses: soared 133.34% in 2023 and later crashed 189.29% in 2024.
  • Dianthus Therapeutics' Other Operating Expenses stood at -$16.1 million in 2022, then surged by 133.34% to $5.4 million in 2023, then crashed by 189.29% to -$4.8 million in 2024.
  • The last three reported values for Other Operating Expenses were -$4.8 million (Q4 2024), $5.4 million (Q4 2023), and -$7.3 million (Q2 2023) per Business Quant data.